# US 2010/0074950 A1 · Anti-diabetic combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074950 A1
- Document ID: US20100074950A1
- Status: Published application
- Kind: A1
- Application number: 12/560,292
- Filed: 2009-09-15
- Published: 2010-03-25
- Earliest claimed: 2007-03-14
- Assignees: Nectid Inc.
- Inventors: Ramesh Sesha
- Web page: https://patentgrep.com/patent/US20100074950A1

## CPC

- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition comprising a dipeptidyl peptidase IV inhibitor and a slow release biguanide is provided. A method for treating diabetes in a patient in need thereof including administering an anti-diabetic combination comprising a DPP inhibitor and a slow release biguanide is also provided.

## Claims

### Claim 1

A pharmaceutical composition for treating diabetes comprising:
a) a slow release core comprising metformin or a pharmaceutically acceptable salt thereof, and optionally one pharmaceutically acceptable excipient, and
b) an immediate release coating comprising a dipeptidyl peptidase IV inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dipeptidyl peptidase IV inhibitor is Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Dutogliptin, GRC-8200, SSR-162369, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the excipient is an adjuvant, a preservative, an antioxidant, a thickening agent, a chelating agent, an antifungal agent, an antibacterial agent, an isotonic agent, a flavoring agent, a sweetening agent, an anti-foaming agent, a colorant, a diluent, a moistening agent, a parietal cell activator, or combination of thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least 95% of the dipeptidyl peptidase IV inhibitor is released within 120 minutes when tested in a USP type 1 apparatus, at pH 2.0 in a HCl-0.3M KCl buffer solution.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4 wherein at least 95% of the dipeptidyl peptidase IV inhibitor is released within 90 minutes when tested in a USP type 1 apparatus, at pH 2.0 in a HCl-0.3M KCl buffer solution.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dipeptidyl peptidase IV inhibitor is Sitagliptin phosphate.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dipeptidyl peptidase IV inhibitor is Vildagliptin.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dipeptidyl peptidase IV inhibitor is saxagliptin.

### Claim 9

A method for treating diabetes comprising administering to a patient in need thereof a pharmaceutical composition comprising slow release metformin or a pharmaceutically acceptable salt thereof; and a dipeptidyl peptidase IV inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the dipeptidyl peptidase IV inhibitor is Sitagliptin, Vildagliptin, Saxagliptin, Alogliptin, Dutogliptin, GRC-8200, SSR-162369, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the dipeptidyl peptidase IV inhibitor is Sitagliptin phosphate.

### Claim 12 (depends on 10)

The method of claim 10, wherein the dipeptidyl peptidase IV inhibitor is Vildagliptin.

### Claim 13 (depends on 10)

The method of claim 10, wherein the dipeptidyl peptidase IV inhibitor is saxagliptin.

### Claim 14 (depends on 10)

The method of claim 10, wherein the dipeptidyl peptidase IV inhibitor is alogliptin.

### Claim 15 (depends on 10)

The method of claim 10, wherein the dipeptidyl peptidase IV inhibitor is dutogliptin.

### Claim 16 (depends on 1)

A pharmaceutical kit wherein the kit includes a composition of claim 1 comprising a dipeptidyl peptidase IV inhibitor or a pharmaceutically acceptable salt thereof and slow release metformin or a pharmaceutically acceptable salt thereof.

### Claim 17

A pharmaceutical composition comprising a slow release metformin and a dipeptidyl peptidase IV inhibitor, wherein the said composition exhibits a dissolution profile such that; after two hours from 0 to about 25 percent of metformin is released, after four hours from about 10 to about 45 percent of metformin is released, after eight hours from about 30 to about 90 percent of metformin is released, after twelve hours not less than 50 percent of metformin is released, after sixteen hours not less than 60 percent of metformin is released, when tested in a USP type 1 apparatus, at pH 2.0 in a HCl-0.3M KCl buffer solution.
